Verification of Current Risk Scores for Kawasaki Disease in Korean Children

The purpose of this study was to evaluate and assess the compatibility of current risk scoring systems from Japan that were developed to predict intravenous immunoglobulin (IVIG) resistance in patients with Kawasaki disease (KD). The authors previously investigated another prediction model for patients with refractory KD in Korea. A retrospective study involving 350 patients with KD who were admitted between January 2014 and December 2015 was performed. Patients younger than 2 years were excluded for the propensity score matching in this study. Patients were classified into IVIG responders and IVIG resistance groups. The well-known Harada, Kobayashi, and Egami risk scores were calculated for each patient, and the proportion of high-risk patients was compared between the two groups for each risk score. Logistic regression analysis revealed that platelets, C-reactive protein (CRP) levels, and aspartate aminotransferase levels were independent predictors of IVIG resistance. Multivariate analysis suggested that platelets and CRP were risk factors. Risk-scoring systems from Japan have good specificity but low sensitivity. Among the three risk scoring systems, the Kobayashi risk score demonstrated significant differences between the IVIG resistance and IVIG responder groups in Korean patients with KD. It is very important to identify IVIG-resistant patients to protect them from ongoing coronary arterial lesion(s); therefore, early prediction and timely optimal additional treatment is of significant benefit. It would be helpful to construct a highly sensitive, exclusive scoring system for Korean patients with KD.

[1]  Bo Young Kim,et al.  Non-Responders to Intravenous Immunoglobulin and Coronary Artery Dilatation in Kawasaki Disease: Predictive Parameters in Korean Children , 2016, Korean circulation journal.

[2]  S. Ohga,et al.  Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin. , 2016, International journal of cardiology.

[3]  C. Hoggart,et al.  Predicting IVIG resistance in UK Kawasaki disease , 2015, Archives of Disease in Childhood.

[4]  Sohee Park,et al.  Epidemiologic Features of Kawasaki Disease in South Korea: Data from Nationwide Survey, 2009–2011 , 2014, The Pediatric infectious disease journal.

[5]  Y. Kashiwagi,et al.  Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients , 2013, International journal of rheumatic diseases.

[6]  Sang Bum Lee,et al.  Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease , 2013, Korean journal of pediatrics.

[7]  Z. Du,et al.  Novel Predictors of Intravenous Immunoglobulin Resistance in Chinese Children with Kawasaki Disease , 2013, The Pediatric infectious disease journal.

[8]  S. Colan,et al.  Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. , 2011, The Journal of pediatrics.

[9]  B. McCrindle,et al.  Improved Classification of Coronary Artery Abnormalities Based Only on Coronary Artery z-Scores After Kawasaki Disease , 2010, Pediatric Cardiology.

[10]  R. Sundel,et al.  Atypical and incomplete Kawasaki disease. , 2009, Best practice & research. Clinical rheumatology.

[11]  J. Newburger,et al.  Resistance to intravenous immunoglobulin in children with Kawasaki disease. , 2008, The Journal of pediatrics.

[12]  S. Kurotobi,et al.  Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment , 2006, European Journal of Pediatrics.

[13]  T. Matsuishi,et al.  Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. , 2006, The Journal of pediatrics.

[14]  Tomio Kobayashi,et al.  Prediction of Intravenous Immunoglobulin Unresponsiveness in Patients With Kawasaki Disease , 2006, Circulation.

[15]  K. Nishigaki,et al.  Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease , 2005, Pediatrics international : official journal of the Japan Pediatric Society.

[16]  T. Ichiyama,et al.  Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease , 2005, Clinical and experimental immunology.

[17]  Yoshikazu Nakamura,et al.  Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition) , 2005, Pediatrics international : official journal of the Japan Pediatric Society.

[18]  K. Harada Intravenous γ‐Globulin Treatment in Kawasaki Disease , 1991 .

[19]  G. Schwartz,et al.  Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. , 1978, The Journal of pediatrics.

[20]  JCSJointWorkingGroup Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[21]  K. Harada Intravenous gamma-globulin treatment in Kawasaki disease. , 1991, Acta paediatrica Japonica : Overseas edition.

[22]  T. Enright,et al.  Kawasaki syndrome. , 1990, Annals of allergy.